DOCSLIB.ORG

D.C. Act 22-550

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
D.C. Act 22-550 ENROLLED ORIGINAL AN ACT D.C. ACT 22-550 IN TFIE COUNCIL OF"IIIE DISTRICT OF COLUMBIA DEGEMBER 26,2018 To amcnd, on an emergency basis, due to congressional review, the District of Columbia ljniform Controlled Substances Act of 198 I to add certain classes and substances to the list of Schedule I controlled substances. BE IT ENACTED BY THE COTJNCIL OF THE DISTRICT OF COLUMBIA, That this act may be cited as the "Revised Synthetics Abatement and F-ull Enforcement Drug Control Congressional Review Emergency Amendment Act of 20 I 8". Sec. 2. The District of Columbia Uniform Controlled Substances Act of 1981, effective August 5, 1981 (D.C. Law 4-29: D.C. Official Code $ 48-901.01 et seq.), is amended as follows: (a) Section 102(27) (D.C. Official Code $ 48-901.02(27) is amended as fo[[ows: ( I ) Strike the phrase "as used in section 204(l) and section 206( IXD)" and insert the phrase "as used in section 204(3), (5), and (6) and section 206( I )(D)" in its place. (2) Strike the phrase "As used in section 204(3)" and insert the phrase "As used in section 204(3). (5), and (6)" in its place. (b) Section 204 (D.C. Official Code $ 48-902.04) is amended as follows: (1) Paragraph (3) is amended as lollows: (A) The lead-in language is amended by striking the phrase "(for purposes of this paragraph only. the term "isomer" includes the optical, position, and geometric isomers):" and insening a colon in its place. (B) New subparagraphs (G-i) through (G-xii) are added to read as follows: "(G-i) 251-NBOMe (also known as 4-iodo-2,5-dimethoxy-N-[(2- methoxyphenyl)methyl]-benzeneethanamine); "(G-ii) 258-NBOMe (also known as 4-bromo-2.5-dimethoxy-N-[(2- methoxyphenyl)methyll-benzeneethanamine); "(C-iiD 25C-NBOMe (also known as 2-(4-chloro-2,5-dimethoxyphenyl)- N-(2-mcthoxybenzyl)ethanamine); "(G-iv) 5-APB (also known as a-methyl-5-benzofuranethanamine); ENROLLED OR]GINAL "(G-v) 5-APDB (also known as 2,3-dihydro-o-methyl-5- benzof uranethanamine) ; "(G-vi) 6-APB (also known as o-methyl-6-benzofuranethanamine); "(G-vii) 6-APDB (also known as 2,3-dihydro-o-methyl-6- benzofuranethanamine) ; "(G-viii) 3-methoxy-PCE (also known as N-ethyt-1 -(3-methoxyphenyl)- cyclohexanamine); "(G-ix) 3-methoxy-PCP (also knor.vn as 1 -[ -(3- methoxyphenyl)cyclohexyll -piperidine) ; "(G-x) 4-methoxy-PCP (also known as l-[1-(4- methoxyphenyl)cyclohexyll -piperidine); "(G-xi) 5-methoxy-DALT , also known as: "(i) 5-MeO-DALT; or "(ii) 5-methoxy-N,N-di-2-propen-l -yl- I H-indole-3-ethanamine; "(G-xii) 4-acetoxy DMT, also known as: "(i) 4-AcO-DMT; or "(ii) 3-[2-(dimethylamino)ethyl]- I H-indol-4-ol-4-acetate; (C) A new subparagraph (M-i) is added to read as follows: "(M-i) Methoxetamine (also known as 2-(ethylamino)-2-(3- methoxyphenyl)cyclohexanone);". (D) Subparagraph (JJ) is amended by striking the phrase "; and" and inserting a semicolon in its place. (E) Subparagraph (KK) is amended by striking the semicolon and inserting the phrase "; and" in its place. (F) A new subparagraph (LL) is added to read as follows: "(LL) Cathinone;". (2) Paragraph (5) is amended to read as follows: "(5) As used in this paragraph, the term "synthetic cathinones" includes any material, compound, mixture, or preparation that is not otherwise listed as a controlled substance in this schedule or in Schedules II through V, is not approved by the Food and Drug Administration as a drug, and is structurally derived from or contains any quantity of the following substances, their salts, isomers, homologues, analogues, and salts of isomers, homologues, and analogues, unless specifrcally excepted, whenever the existence ofthese salts, isomers, homologues, analogues, and salts of isomers, homologues, and analogues is possible within the specific chemical designation: "(A) Classified Synthetic Cathinones: "(i) Cathinones. Any compound, other than methylnenedioxy cathinones and pyrrolidine cathinones, containing a 2-amino- 1-propanone structure with substitution at the l-position with a monocyclic ring system, with or without alkyl, alkoxyl, or 2 ENROI,I,E,D ORIGINAL halo substitutions, and a substitution at the nitrogen atom by an alkyl group, cycloalkyl group, or incorporation into a heterocyclic structure. Examples of this structural class include: "(I) Mephedrone, also known as: "(aa) 2-(methylamino)-1-(4-methylphenyl)-1- propanone; "(bb) 4-MeMC: "(cc) 4-Methylmethcathinone ; "(dd) 4-Methylephedrone; or "(ee) 4-MMC; "(ll) Dimethylcathinone, also known as: "(aa) 2-(dimethylamino)- 1 -phenyl-1 -propanone; or "(bb) N,N-Dimethylcathinone; "(III) Ethcathinone, also knou,n as: "(aa) 2-(ethylamino)-1-phenyl-1-propanone; "(bb) Ethylcathinone; "(cc) N-Ethylcathinone; or "(dd) 2-Ethylaminobuphedro; "(IV) Buphedrone, also known as; "(aa) 2-(methylamino)-1-phenylbutan-l-one; or "(bb) MABP; "(V) 3,4-DMMC, also known as: "(aa) I-(3,4-dimethylphenyl)-2-(methylamino)-1- propanone; or "(bb) 3,4-Dimethylmethcathinone; "(VI) EMC, also known as: "(aa) l-(4-ethylphenyl)-2-(methylamino)propan-1- one; "(bb) 4-EMC; or "(cc) 4-Ethylmethcathinone; "(VII) Fluoromethcathinone (also krown as 1-(4- fl uorophenyl)-2-(methylamino) propan- 1 -one) ; "(VIII) 3-FMC, also known as: "(aa) 3-fluoro-N-methylcathinone); or "(bb) 1 -(3-fluorophenyl)-2-(methylamino)propan- l - one; '(lX) 4-FMC, also known as: "(aa) 1-(4-fluorophenyl)-2-(methylamino)propan-1- one; "(bb) 4-fluoro-N-methylcathinone; or J ENROLLED ORIGINAL "(cc) Flephedrone; "(X) 4-MeBP, also known as: "(aa) 2-(methylamino)- 1 -(4-methylphenyl)- I - butanone; "(bb) 4-Methylbuphedrone; "(cc) 4-methyl BP; or "(dd) 4-MeMABP; "(XI) 3-MEC, also known as: "(aa) 2-(ethylamino )-1-(m+olyl)propan-l-one; or "(bb) 3-Methyl-N-ethylcathinone; "(XII) 4-MEC, also known as: "(aa) 2-(ethylamino)-l -(4-methylphenyl)-l- propanone; or "(bb) 4-Methyl-N-ethylcathinone; "(XIID 3-MMC, also known as: "(aa) 2-(methylamino)- 1 -(3-methylphenyl)- I - propanone; "(bb) 3-methyl MS; or "(cc) 3-Methylmethcathinone; "(XIV) Methedrone (also known as l-(4-methoxyphenyl)- 2-(methylamino)- 1 -propanone); and "(XV) Pentedrone (also known as 2-(methylamino)- 1 - phenylpentan- I -one); "(ii) Methylenedioxy Cathinones. Any compound containing a 2- amino- l-propanone structure with substitution at the l-position with a monocyclic or fused polycyclic ring system and a substitution at any position ofthe ring system with an alkyl, haloalkyl, halogen, alkylenedioxy, or alkoxy group, whether or not further substituted at anv position on the ring system to any extent. Examples of this structural class include: "(l) 3-fl uoromethylone; "(ll) Methylone, also known as "(aa) l -(1,3 -benzodioxol-5-yl)-2-(methylamino)- 1 - propanone; or "(bb) 3,4-Methylenedioxy-N-methylcathinone); "flII) N-ethyl Pentylone, also known as: "(aa) Ephylone; or "(bb) 1 -( 1,3-benzodioxol-5-yl)-2-(ethylamino)- 1 - pentanone; *(IV) bk-MDDMA, also known as 4 ENROLLED ORIGINAL "(aa) I -( I ,3-benzodioxol-5-yl)-2- (dimethylamino)propan- I -one; "(bb) Dimethylone; "(cc) N,N-dimethyl-3',4' -methylenedioxycathinone; "(dd) N,N-dimethyl-3,4-methylenedioxycathinone ; or "(ee) N,N-Dimethyl MDCATH; "(V) Butylone, also known as 1-( 1,3-benzodioxol-5-yl)-2- (methylamino)butan- I -one); and "(VI) Ethylone, also known as: "(aa) 3,4-Methylenedioxy-N-ethylcathinone; or "(bb) MDEC; "(iii) Pynolidine Cathinones. Any compound containing a 2- amino- 1-propanone structure with substitution at the 1-position with an alkyl, cyclic, or fused polycyclic ring system and a substitution at the 3-position carbon with an alkyl, haloalkyl, halogen, alkoxy or alkylenedioxy group, and a substitution at the nitrogen atom incorporation into a heterocyclic structure, with or without further halogen substitutions. Examples include: "(l) o-PVP (also known as o-pyrrolidinopentiophenone); "(ll) o-pynolidinopropiophenone, also knor.m as: "(aa) l-phenyt-2-(1-pynolidinyl)-l-propanone; or "(bb) u-PPP; "(III) a-PBP, also known as: "(aa) 1 -phenyl-2-(1 -pyrrolidinyl)-1 -butanone; or " (bb) u-pyrrolidinobutiophenone; "(IV) MDPBP, also known as: "(aa) l-(1,3-benzodioxol-5-yl)-2-(1-pyrrolidinyl)-1- butanone; "(bb) 3,4-Methylenedioxy-o- Pynolidinobutiophenone; or "(cc) 3,4-MDPBP; '(V) MDPPP, also known as: "(aa) 1 -(1,3-benzodioxol-5-yl)-2-( 1 -pynolidinyl)- I - propanone; or "(bb) 3,4-Methylenedioxy-o- Pynolidinopropiophenone; "(VI) MDPV, also known as: "(aa) I -(1,3-benzodioxol-5-yl)-2-(1 -pyrrotidinyl)-1 - pentanone; or "(bb) 3,4-Methylenedioxy Pyrovalerone; 5 ENROLLED ORIGINAL "(VII) 4-MePPP, also known as "(aa) 4'-methyl-o-Pyrrolidinopropiophenone; "(bb) 4'-methyl PPP; or "(cc) 2-(pynolidin-l-yl)- 1 -(p-tolyl)propan-l-one; "(VIII) 4'-methyl PHP, also known as: '' (aa) 4'-methyl-o-pyrrolidinohexanophenone; "(bb) MPHP; "(cc) 4'-methyl-o-PHP; or ''(dd) Pva; "(IX) Naphyrone, also known as: " (aa) (RS )- 1 -naphthalen-2-yl-2-pyrrolidin-l- ylpentan- 1-one; or "(bb) Naphpyrovalerone; and '(X) C-PVP, also known as: "(aa) 4-Chloro-u-PVP; or "(bb) l-(4-chlorophenyl)-2-(pyrrolidin-1-yl)pentan- 1-one; or "(iv) Piperazine Stimulants. Any compound containing or structurally derived from a piperazine, or diethylenediamine, structure with or without substitution at one of the nitrogen atoms ofthe piperazine ring to any extent, including alkyl, cycloalkyl, or fused ring systems, with or without further halogen substitutions. Examples include: "(l) BZP, also known as: "(aa) 1 -(phenylmethyl)-piperazine; "(bb) I -Benzylpiperazine; or "(cc) N-Benzylpiperazine; and "(II) TMFPP, also known as: "(aa) 1 - [3-(trifl uoromethyl)pheny[] -piperazine ; "(bb) I -(m-Trifluoromethylphenyl) piperazine; or "(cc) 3 -Tri fl uoromethylphenylpiperazine.
Load more

Recommended publications
  • Forensic Science
    Anal. Chem. 1999, 71, 235R-255R Forensic Science T. A. Brettell* Forensic Science Bureau, New Jersey State Police, Box 7068, West Trenton, New Jersey 08625 K. Inman California Department of Justice DNA Laboratory, 626 Bancroft Way, Berkeley, California 94710 N. Rudin² 1563 Solano Ave. #506, Berkeley, California 94707 R. Saferstein³ Box 1334, Mount Laurel, New Jersey 08054 Review Contents Canadian Society of Forensic Science, Journal of Forensic Identifica- Drugs and Poisons 235R tion, Forensic Science Review, Analytical Toxicology, Electrophoresis, Ethanol and Volatiles 235R and BioTechniques, as well as Chemical Abstracts Selects: Forensic Cannabinoids 236R Chemistry. Our survey encompasses the period from January 1997 Morphine and Related Narcotics 237R through December 1998. Because of the normal delays in the Cocaine 237R abstraction of journal articles by Chemical Abstracts, some work Amphetamines 238R covering this period will inadvertently be omitted. Hopefully these Barbiturates 239R references will be included in the next biennial review. Benzodiazepines 239R The format selected for this survey divides coverage into three Miscellaneous Drugs and Poisons 239R distinct areas: drug and poisons, forensic DNA analysis, and trace General Procedures 241R Forensic DNA Analysis 242R evidence. Within the scope of each of the areas, articles have been DNA Extraction and Quantitation 242R selected to describe current forensic science practices in analytical Restriction Fragment Length Polymorphisms 242R chemistry and to outline relevant forensic science research Amplified Fragment Length Polymorphisms 242R interests. To keep our discussion concise and meaningful, we have Short Tandem Repeats 242R limited our survey to drugs regulated under the United States Gender Identification 243R Controlled Substances Act, ethanol, and common poisons.
    [Show full text]
  • Case: 1:18-Cr-00474-JRA; Zheng ECF Filed Indictment
    Case: 1:18-cr-00474-JRA Doc #: 1 Filed: 08/17/18 1 of 83. PageID #: 1 IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF OHIO EASTERN DIVISION UNITED STATES OF AMERICA, ) INDICTMENT Plaintiff, ~ JUDGE PO V. ~ CASE10; 18 CR ) Title 21, Sections 33l(a), FUJINO ZHENG, ) 333(b)(7), 35l(d), 841(a)(l), aka, GORDON JIN, ) (a)(2), (b)(l)(A), (b)(l)(C), (h), aka, MR. JIN, ) 843(c)(2)(A), 846, 848, 853, aka, GORDON ZHENG, ) 952(a), 959(a), 960(a)(l) and (3), aka, JINXINXIN, ) (b)(1 ), (b )(3), 963, and 970, aka, FU JING ZHENG, ) Title 18, Sections 1956(a)(2), (h), aka, DENG GAO, ) and 2, GUANGHUA ZHENG, ) United States Code aka, GUANG HUA ZHENG, ) ) Defendants. ) ) COUNT 1 (Conspiracy to Manufacture, Distribute, and Possess with the Intent to Distribute Controlled Substances and Controlled Substance Analogues Resulting in Death, 21 U.S.C. §§ 841(a)(l), (b)(l)(A), (b)(l)(C), all in violation of 21 U.S.C. § 846) The Grand Jury charges: 1. From on or about January 1, 2008 to the Present, the exact dates unknown to the Grand Jury, in the Northern District of Ohio, Eastern Division, the People's Republic of China, and elsewhere, Defendants FUJINO ZHENG, aka GORDON JIN, aka MR. JIN, aka GORDON ZHENG, aka JINXINXIN, aka FU JING ZHENG, aka DENG GAO; GUANGHUA ZHENG, aka GUANG HUA ZHENG; Guangfu Z.; Guifeng C.; Songyan J.; Longbao Z.; Qinghua Y., aka Jason Yen; Lynn X.; Leroy S.; (individuals whose names are known to the Grand Jury); Global United Biotechnology; Global United Holdings; Global Biotech, Inc.; Global Holdings, Inc.; Top Lab RC; Global RC; Golden Chemicals; Cambridge Chemicals; Wonda Science; OneChem; Case: 1:18-cr-00474-JRA Doc #: 1 Filed: 08/17/18 2 of 83.
    [Show full text]
  • Special Drug Groups 2
    Copyright Material – Provided by Taylor & Francis Special Drug Groups 2 Acetylcholinesterase Inhibitors While acetylcholinesterase inhibitors were historically used as pesticides and herbicides, in recent years they have been used to develop medica- tions to treat Alzheimer’s disease and myasthenia gravis. Commonly, their toxicity is measured by the percentage of acetylcholinesterase (ACh) activ- ity with toxicity beginning 20% below the level of normal activity (or 80% activity level) and becoming pronounced by 50% activity level. Severe tox- icity and death occur at 90% suppression (measured activity level = 10%). Postmortem testing should utilize the red blood cell (RBC), ACh as it better reflects neural ACh activity. Table 2.1 is a non-comprehensive list of common drugs, nerve agents, and insecticide/pesticides that are acetylcholinesterase inhibitors. 3 Copyright Material – Provided by Taylor & Francis 4 Table 2.1 Acetylcholinesterase Inhibitors Drugs—Alzheimer’s disease Drugs—myasthenia gravis Drugs—glaucoma Poisons—nerve agents Donepezil (Aricept) Ambenonium (Mytelase) Demecarium (Humorsol) Cyclosarin Galantamine (Razadyne, Reminyl, Edrophonium (Tensilon, Enlon, Echothiophate (Phospholine iodide) Sarin Nivalin) Reversol) Soman Medical for ExaminersHandbook Toxicology Forensic of Huperzine A Neostigmine (Prostigmin) Tabun Ladostigil Physostigmine (Antilirium) VX Metrifonate Pyridostigmine (Mestinon, VE Rivastigmine (Exelon) Regonol) VG Tacrine (Cognex) VM Insecticides or pesticides Acephate (Orthene) Dichlorvos (DDVP, Vapona) Formetanate
    [Show full text]
  • Structure-Activity Relationships of Synthetic Cathinones
    Structure-Activity Relationships of Synthetic Cathinones Richard A. Glennon and Małgorzata Dukat Abstract Until recently, there was rather little interest in the structure-activity relationships (SARs) of cathinone analogs because so few agents were available and because they represented a relatively minor drug abuse problem. Most of the early SAR was formulated on the basis of behavioral (e.g., locomotor and drug discrimination) studies using rodents. With the emergence on the clandestine market in the last few years of a large number of new cathinone analogs, termed “synthetic cathinones”, and the realization that they likely act at dopamine, norepi- nephrine, and/or serotonin transporters as releasing agents (i.e., as substrates) or reuptake inhibitors (i.e., as transport blockers), it has now become possible to better examine their SAR and even their quantitative SAR (QSAR), in a more effective and systematic manner. An SAR picture is beginning to emerge, and key structural features, such as the nature of the terminal amine, the size of the α-substituent, stereochemistry, and the presence and position of aromatic substituents, are being found to impact action (i.e., as releasing agents or reuptake inhibitors) and trans- porter selectivity. Keywords DAT • Methcathinone • Monoamine transporters • NET • QSAR • SAR • SERT Contents 1 Introduction ................................................................................... 20 2 Early SAR of Cathinone ..................................................................... 23 3 The Methcathinone
    [Show full text]
  • COMMITTEE/SUBCOMMITTEE AMENDMENT Bill No. HB 1175 (2012) Amendment No
    COMMITTEE/SUBCOMMITTEE AMENDMENT Bill No. HB 1175 (2012) Amendment No. 1 COMMITTEE/SUBCOMMITTEE ACTION ADOPTED (Y/N) ADOPTED AS AMENDED (Y/N) ADOPTED W/O OBJECTION (Y/N) FAILED TO ADOPT (Y/N) WITHDRAWN (Y/N) OTHER 1 Committee/Subcommittee hearing bill: Criminal Justice 2 Subcommittee 3 Representative Ingram offered the following: 4 5 Amendment 6 Remove lines 147-236 and insert: 7 84. Naphyrone (naphthylpyrovalerone). 8 85. N-N-Dimethyl-3,4-methylenedioxycathinone. 9 86. N-N-Diethyl-3,4-methylenedioxycathinone. 10 87. 3,4-methylenedioxy-propiophenone. 11 88. 2-Bromo-3,4-Methylenedioxypropiophenone. 12 89. 3,4-methylenedioxy-propiophenone-2-oxime. 13 90. N-Acetyl-3,4-methylenedioxycathinone. 14 91. N-Acetyl-N-Methyl-3,4-Methylenedioxycathinone. 15 92. N-Acetyl-N-Ethyl-3,4-Methylenedioxycathinone. 16 93. Bromomethcathinone. 17 94. Buphedrone (alpha-methylamino-butyrophenone). 18 95. Eutylone (beta-Keto-Ethylbenzodioxolylbutanamine). 19 96. Dimethylcathinone. 964151 - h1175-line147.docx Published On: 1/13/2012 6:13:24 PM Page 1 of 4 COMMITTEE/SUBCOMMITTEE AMENDMENT Bill No. HB 1175 (2012) Amendment No. 1 20 97. Dimethylmethcathinone. 21 98. Pentylone (beta-Keto-Methylbenzodioxolylpentanamine). 22 99. (MDPPP) 3,4-Methylenedioxy-alpha-pyrrolidinopropiophenone. 23 100. (MDPBP) 3,4-Methylenedioxy-alpha-pyrrolidinobutiophenone. 24 101. Methoxypyrrolidinopropiophenone (MOPPP). 25 102. Methylpyrrolidinohexiophenone (MPHP). 26 103. Benzocyclidine (BCP) or benzothiophenylcyclohexylpiperidine 27 (BTCP). 28 104. Fluoromethylaminobutyrophenone (F-MABP). 29 105. Methoxypyrrolidinobutyrophenone (MeO-PBP). 30 106. Ethylpyrrolidinobutyrophenone (Et-PBP). 31 107. 3-Methyl-4-Methoxymethcathinone (3-Me-4-MeO-MCAT). 32 108. Methylethylaminobutyrophenone (Me-EABP) 33 109. Methylaminobutyrophenone (MABP). 34 110. Pyrrolidinopropiophenone. 35 111. Pyrrolidinobutiophenone (PBP). 36 112. Pyrrolidinovalerophenone (PVP).
    [Show full text]
  • 2012 COMMITTEE AMENDMENT Bill No. CS for SB 1502
    Florida Senate - 2012 COMMITTEE AMENDMENT Bill No. CS for SB 1502 370844 Ì3708442Î LEGISLATIVE ACTION Senate . House Comm: RCS . 02/16/2012 . The Committee on Health Regulation (Fasano) recommended the following: 1 Senate Amendment 2 3 Delete lines 137 - 237 4 and insert: 5 71. N,N-Diallyl-5-Methoxytryptamine. 6 72. DOI (4-Iodo-2,5-dimethoxyamphetamine). 7 73. DOC (4-Chloro-2,5-dimethoxyamphetamine). 8 74. 2C-E (4-Ethyl-2,5-dimethoxyphenethylamine). 9 75. 2C-T-4 (2,5-Dimethoxy-4-isopropylthiophenethylamine). 10 76. 2C-C (4-Chloro-2,5-dimethoxyphenethylamine). 11 77. 2C-T (2,5-Dimethoxy-4-methylthiophenethylamine). 12 78. 2C-T-2 (2,5-Dimethoxy-4-ethylthiophenethylamine). Page 1 of 5 2/16/2012 9:40:44 AM HR.HR.03514 Florida Senate - 2012 COMMITTEE AMENDMENT Bill No. CS for SB 1502 370844 Ì3708442Î 13 79. 2C-T-7 (2,5-Dimethoxy-4-(n)-propylthiophenethylamine). 14 80. 2C-I (4-Iodo-2,5-dimethoxyphenethylamine). 15 81. Butylone (beta-keto-N-methylbenzodioxolylpropylamine). 16 82. Ethcathinone. 17 83. Ethylone (3,4-methylenedioxy-N-ethylcathinone). 18 84. Naphyrone (naphthylpyrovalerone). 19 85. N-N-Dimethyl-3,4-methylenedioxycathinone. 20 86. N-N-Diethyl-3,4-methylenedioxycathinone. 21 87. 3,4-methylenedioxy-propiophenone. 22 88. 2-Bromo-3,4-Methylenedioxypropiophenone. 23 89. 3,4-methylenedioxy-propiophenone-2-oxime. 24 90. N-Acetyl-3,4-methylenedioxycathinone. 25 91. N-Acetyl-N-Methyl-3,4-Methylenedioxycathinone. 26 92. N-Acetyl-N-Ethyl-3,4-Methylenedioxycathinone. 27 93. Bromomethcathinone. 28 94. Buphedrone (alpha-methylamino-butyrophenone). 29 95. Eutylone (beta-Keto-Ethylbenzodioxolylbutanamine). 30 96.
    [Show full text]
  • The Real Deal on Synthetic Drugs
    2 presentations (part one) table of contents Community Drug Early Warning System: Recent Findings for Washington, DC 3 Bath Salts and Spice: Facts and Strategies 36 A Forensic Perspective on Synthetic Drug Trends 64 The Real Deal on Synthetic 3 Drugs: Recent Findings for Washington, DC July 17, 2014 Presented by: Eric D. Wish, Ph.D. Erin Artigiani, MA Center for Substance Abuse Research University of Maryland College Park www.cesar.umd.edu [email protected] 4 CESAR is… • Founded in 1990 as an interdisciplinary research center at the University of Maryland, College Park • Conducts policy-relevant research in all areas related to substance abuse • Maintains a clearinghouse of substance abuse information • Publishes the weekly CESAR Fax • Specializes in applied epidemiology 5 6 Source: Center for Substance Abuse Research (CESAR), Community Drug Early Warning System (CDEWS), December 2013. 2014* 13.0 2013 2012 2011 2010 2009 2008 2007 2006 7 2005 2004 2003 2002 2001 2000 District Columbia. forthe of Agency 1999 1998 Services 1997 Pretrial Pretrial June 2014 June 1996 - 1995 1994 1993 1992 1984 1991 1990 1989 1988 1987 1986 1985 1984 SOURCE: Adapted by from the by CESAR from data SOURCE: Adapted 0 Percentage of Washington, DC, Adult DC, of Washington, Percentage 20 10 40 30 60 50 70 Arrestees Testing Positive for Cocaine: Cocaine: for Positive Testing Arrestees Arrestees Testing Positive for Marijuana: for Positive Testing Arrestees 10 20 30 40 50 60 70 Percentage of Washington, DC, Juvenile Juvenile DC, of Washington, Percentage 0 1987 SOURCE: Adapted by from the by CESAR from data SOURCE: Adapted 1988 1989 1990 1991 1992 8 1993 1994 1987 1995 1996 1997 1998 - June 2014 June Pretrial Pretrial 1999 2000 Services Services 2001 2002 Agency District Columbia.
    [Show full text]
  • ENGR. SB NO. 12 Page 1 1 2 3 4 5 6 7 8 9 10 11
    1 ENGROSSED SENATE BILL NO. 12 By: Standridge of the Senate 2 and 3 Kannady of the House 4 5 6 An Act relating to Uniform Controlled Dangerous Substances Act; amending 63 O.S. 2011, Section 2-204, 7 as last amended by Section 1, Chapter 207, O.S.L. 2019 (63 O.S. Supp. 2020, Section 2-204), which 8 relates to Schedule I; modifying inclusions; and providing an effective date. 9 10 11 BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA: 12 SECTION 1. AMENDATORY 63 O.S. 2011, Section 2-204, as 13 last amended by Section 1, Chapter 207, O.S.L. 2019 (63 O.S. Supp. 14 2020, Section 2-204), is amended to read as follows: 15 Section 2-204. The controlled substances listed in this section 16 are included in Schedule I and include any material, compound, 17 mixture or preparation that contains any quantity of the following 18 hallucinogenic substances, their salts, isomers and salts of 19 isomers, unless specifically excepted, when the existence of these 20 salts, isomers and salts of isomers is possible within the specific 21 chemical designation. 22 A. Any of the following opiates, including their isomers, 23 esters, ethers, salts, and salts of isomers, esters, and ethers, 24 unless specifically excepted, when the existence of these isomers, ENGR. S. B. NO. 12 Page 1 1 esters, ethers, and salts is possible within the specific chemical 2 designation: 3 1. Acetylmethadol; 4 2. Allylprodine; 5 3. Alphacetylmethadol; 6 4. Alphameprodine; 7 5. Alphamethadol; 8 6.
    [Show full text]
  • 1 Councilmember Charles Allen 2 3 4 5 a BILL
    1 ___________________________ 2 Councilmember Charles Allen 3 4 5 6 A BILL 7 8 _____ 9 10 11 IN THE COUNCIL OF THE DISTRICT OF COLUMBIA 12 13 __________ 14 15 16 To amend, on an emergency basis, due to congressional review, the District of Columbia 17 Uniform Controlled Substances Act of 1981 to add certain classes and substances to the 18 list of Schedule I controlled substances. 19 20 BE IT ENACTED BY THE COUNCIL OF THE DISTRICT OF COLUMBIA, That this 21 act may be cited as the “Revised Synthetics Abatement and Full Enforcement Drug Control 22 Congressional Review Emergency Amendment Act of 2018”. 23 Sec. 2. The District of Columbia Uniform Controlled Substances Act of 1981, 24 effective August 5, 1981 (D.C. Law 4-29; D.C. Official Code § 48-901.01 et seq.), is amended as 25 follows: 26 (a) Section 102(27) (D.C. Official Code § 48-901.02(27)) is amended as follows: 27 (1) Strike the phrase “as used in section 204(3) and section 206(1)(D)” and insert 28 the phrase “as used in section 204(3), (5), and (6) and section 206(1)(D)” in its place. 29 (2) Strike the phrase “As used in section 204(3)” and insert the phrase “As used in 30 section 204(3), (5), and (6)” in its place. 31 (b) Section 204 (D.C. Official Code § 48-902.04) is amended as follows: 32 (1) Paragraph (3) is amended as follows: 1 33 (A) The lead-in language is amended by striking the phrase “(for purposes 34 of this paragraph only, the term “isomer” includes the optical, position, and geometric isomers):” 35 and inserting a colon in its place.
    [Show full text]
  • Synthetic Drugs
    San Diego Municipal Code Chapter 5: Public Safety, Morals and Welfare Chapter 12: Land Development Reviews (7-2016) Article 2: Police — Police Regulations — Offenses Against Government Division 33: Manufacturing, Sale, Distribution, and Possession of Federal Schedule I Drugs, Novel Synthetic Drugs, and Novel Psychoactive Drugs (“Manufacturing, Sale, Distribution, and Possession of Federal Schedule I Drugs, Novel Synthetic Drugs, and Novel Psychoactive Drugs” added 6-14-2016 by Emergency Ordinance O-20660 N.S.; effective 6-14-2016.) (“Manufacturing, Sale, Distribution, and Possession of Federal Schedule I Drugs, Novel Synthetic Drugs, and Novel Psychoactive Drugs” added 6-15-2016 by O-20657 N.S.; effective 7-15-2016.) §52.3301 Purpose and Intent The Council for the City of San Diego finds and declares that: (a) Use of Federal Schedule I Drugs, Novel Synthetic Drugs, and Novel Psychoactive Drugs has been documented to cause effects such as hallucinations, agitation, psychosis, aggression, suicidal ideations and death, a significant increase in medical aid emergencies, and may also lead to an increase in associated criminal activity. Some of these drugs are commonly known as “spice” or “bath salts.” (b) Although state and federal laws prohibit some synthetic drugs, drug makers continually alter the composition of the compounds in their products so as to escape the purview of the law. (c) While newly created drugs often go unregulated in California for years, many new drugs receive emergency scheduling in the federal drug schedules within months of their discovery. (d) The purpose and intent of this Division is to provide the City with reasonable measures to address the dangers to the community posed by Federal Schedule I Drugs, Novel Synthetic Drugs, and Novel Psychoactive Drugs.
    [Show full text]
  • Advantages and Limitations of Spectroscopic, Chromatographic and Electrophoretic Methods for the Characterisation of Synthetic Cannabinoids and Synthetic
    Advantages and limitations of spectroscopic, chromatographic and electrophoretic methods for the characterisation of synthetic cannabinoids and synthetic cathinone derivatives Dissertation der Mathematisch-Naturwissenschaftlichen Fakultät der Eberhard Karls Universität Tübingen zur Erlangung des Grades eines Doktors der Naturwissenschaften (Dr. rer. nat.) vorgelegt von Sonja Metternich aus Koblenz Tübingen 2020 Gedruckt mit Genehmigung der Mathematisch-Naturwissenschaftlichen Fakultät der Eberhard Karls Universität Tübingen. Tag der mündlichen Qualifikation: 08.06.2020 Dekan: Prof. Dr. Wolfgang Rosenstiel 1. Berichterstatter: Prof. Dr. Carolin Huhn 2. Berichterstatter: Prof. Dr. Jürgen Pomp Table of contents Table of contents Table of contents ......................................................................................................................... i Abstract ...................................................................................................................................... 3 Zusammenfassung ...................................................................................................................... 4 1 Introduction ............................................................................................................................. 5 1.1 New psychoactive substances - a never ending-story ................................................ 5 1.1.1 Synthetic cannabinoids ........................................................................................... 6 1.1.2 Synthetic cathinone derivatives
    [Show full text]
  • New Psychoactive Substances (NPS)
    New Psychoactive Substances (NPS) LGC Quality Reference ISO 9001 ISO/IEC 17025 ISO Guide 34 materials GMP/GLP ISO 13485 2019 ISO/IEC 17043 Science for a safer world LGC offers the most extensive and up-to-date range of New LGC is a global leader in Psychoactive Substances (NPS) measurement standards, reference materials. reference materials, laboratory services and proficiency testing. With 2,600 professionals working When you make a decision using The challenge The LGC response We are the UK’s in 21 countries, our analytical our resources, you can be sure it’s designated National measurement and quality control based on precise, robust data. And New Psychoactive Substances In response to the ever-expanding LGC Standards provides the widest Measurement services are second-to-none. together, we’re creating fairer, safer, (NPS) continue to be identified, range of NPS being developed, LGC range of reference materials Institute for chemical more confident societies worldwide. and it appears that moves by the has produced a comprehensive available from any single supplier. and bioanalytical As a global leader, we provide the United Nations and by individual range of reference materials that We work closely with leading widest range of reference materials lgcstandards.com countries to control lists of meet the rapidly changing demands manufacturers to provide improved measurement. available from any single supplier. named NPS may be encouraging of the NPS landscape. Many of access to reference materials, the development of yet further these products are produced under with an increasingly large range variants to avoid these controls. the rigorous quality assurance of parameters, for laboratories standards set out in ISO Guide 34.
    [Show full text]